ArticleBMC cancer2012
Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer.
Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Functional Analysis and Clinical Importance of ATP1A1 in Colon Cancer.Annals of surgical oncology · 2023Article
- Emerging Role of Plant-Based Dietary Components in Post-Translational Modifications Associated with Colorectal Cancer.Life (Basel, Switzerland) · 2023Review
- Article
- Comparison of Gut Microbiome in Human Colorectal Cancer in Paired Tumor and Adjacent Normal Tissues.OncoTargets and therapy · 2020Article
- MEK5/ERK5 activation regulates colon cancer stem-like cell properties.Cell death discovery · 2019Article
- Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein.Journal of carcinogenesis · 2018Review
- Oncogenic signaling of MEK5-ERK5.Cancer letters · 2017Review
- The role of MAPK signaling pathway in the Her-2-positive meningiomas.Oncology reports · 2016Article
- MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.Oncotarget · 2016Article
- CCAT1: a pivotal oncogenic long non-coding RNA in human cancers.Cell proliferation · 2016Review
- ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation.Nature communications · 2016Article
- MEK5 overexpression is associated with the occurrence and development of colorectal cancer.BMC cancer · 2016Article
- SATB2 suppresses gastric cancer cell proliferation and migration.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.Cell death & disease · 2015Article
- MEK and the inhibitors: from bench to bedside.Journal of hematology & oncology · 2013Review
- The Investigation ofIn vivo (Athens, Greece)Article
- Multi-omics Investigations of Immune Microenvironment of Human Colorectal Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation of MEK5 in many cancers is associated with carcinogenesis through aberrant cell proliferation. In this study, we determined the level of phosphorylated MEK5 (pMEK5) expression in human colorectal cancer (CRC) tissues and correlated it with clinicopathologic data.
methodspMEK5 expression was examined by immunohistochemistry in a tissue microarray (TMA) containing 335 clinicopathologic characterized CRC cases and 80 cases of nontumor colorectal tissues. pMEK5 expression of 19 cases of primary CRC lesions and paired with normal mucosa was examined by Western blotting. The relationship between pMEK5 expression in CRC and clinicopathologic parameters, and the association of pMEK5 expression with CRC survival were analyzed respectively.
resultspMEK5 expression was significantly higher in CRC tissues (185 out of 335, 55.2%) than in normal tissues (6 out of 80, 7.5%; P < 0.001). Western blotting demonstrated that pMEK5 expression was upregulated in 12 of 19 CRC tissues (62.1%) compared to the corresponding adjacent nontumor colorectal tissues. Overexpression of pMEK5 in CRC tissues was significantly correlated to the depth of invasion (P = 0.001), lymph node metastasis (P < 0.001), distant metastasis (P < 0.001) and high preoperative CEA level (P < 0.001). Consistently, the pMEK5 level in CRC tissues was increased following stage progression of the disease (P < 0.001). Analysis of the survival curves showed a significantly worse 5-year disease-free (P = 0.002) and 5-year overall survival rate (P < 0.001) for patients whose tumors overexpressed pMEK5. However, in multivariate analysis, pMEK5 was not an independent prognostic factor for CRC (DFS: P = 0.139; OS: P = 0.071).
conclusionspMEK5 expression is correlated with the staging of CRC and its expression might be helpful to the TNM staging system of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.